84 Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)

Ardizzoni, Andrea; Hansen, H.H.; Dombernowsky, P; Kaplan, Susan S.; Postmus, P.E.; Gamucci, Teresa; Schaefer, Brigitte; Wanders, J.; Rweij, J.

doi:10.1016/0959-8049(95)95336-5

Cited by 14 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ovarian carcinoma, Topo has shown promising phase II activity with reported response rates of around 20% in relapsed patients (Gore et al, 1996). Activity of Topo has also been reported for NSCLC (Perez-Soler et al, 1996), SCLC (Ardizzoni et al, 1994;Shiller et al, 1994), soft tissue sarcoma (Eisenhauer et al, 1994) and breast cancer (Chang et al, 1995). In renal cell cancer (Ilson et al, 1993;Law et al, 1994) and colorectal cancer (Sugarman et al, 1994) the drug appears inactive.…”

Section: Resultsmentioning

confidence: 88%

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

Jonsson

Fridborg²,

Csòka³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary The cytotoxic activity and cross-resistance pattern of the novel topoisomerase inhibitor topotecan (Topo) were investigated in ten cell lines, representing different mechanisms of cytotoxic drug resistance, and in 218 fresh human tumour samples using the fluorometric microculture cytotoxicity assay (FMCA). Resistance to Topo in the cell lines was associated with expression of the multidrug resistanceassociated protein (MRP), whereas the cell lines with P-glycoprotein (P-gp), topoisomerase 11 and glutathione-associated resistance did not show decreased sensitivity to the drug. Topo was more active in haematological than in solid tumour samples, but substantial activity was observed in carcinomas of the ovary and breast, sarcoma and childhood solid tumours. Cross-resistance to standard drugs representing different mechanisms of action was generally low in patient cells. The effect of Topo was better after longer exposure, but this time-dependent effect was largely abolished when adjustment for in vitro exposure was made. Topo showed activity both in proliferative and non-proliferative cell systems. The results indicate that Topo is insensitive to major mechanisms of resistance except for MRP. Proliferation does not seem to be necessary for the effect of Topo, and no superiority for protracted dosing schedules was observed. The results also suggest that, for example, leukaemias, lymphomas, sarcomas and childhood solid tumours may be suitable targets for future phase 11 trials.

show abstract

Section: Resultsmentioning

confidence: 88%

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

Jonsson

Fridborg²,

Csòka³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In phase II studies response rates to chemotherapy was around 24% in chemosensitive patients and only around 10% in chemoresistant patients. Median overall survival was 5-7 months (Perez et al, 1996;Ardizzoni et al, 1997). In a phase III study comparing best supportive care and topotecan in recurrent SCLC grade 3/4 neutropenia was seen in 61%, thrombocytopenia in 38%, anemia in 25% of the patients (O'Brien et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

Altınbaş¹,

Kalender²,

Öven³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171).In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.

show abstract

“…In contrast with non-small cell lung cancer (NSCLC), progress in SCLC has been minimal in the last decades, being topotecan, in 1996, the last approved agent worldwide for the treatment of SCLC (3). For these reasons, SCLC is now considered a recalcitrant cancer.…”

mentioning

confidence: 99%

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Navarro

Felip

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

84 Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)

Cited by 14 publications

References 0 publications

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Contact Info

Product

Resources

About